RecruitingPhase 4NCT06857942
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Sponsor: Eli Lilly and Company
Bellaire, TX · Dallas, TX · Houston, TX · +36 more sites